Pacific Biosciences of California, Inc.PACBNASDAQ
Loading
Gross Profit Growth Recovery in ProgressRecovering
Percentile Rank56
5Y CAGR-28.9%
Year-over-Year Change
Year-over-year gross profit growth rate
5Y CAGR
-28.9%/yr
Long-term compound
Percentile
P56
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 11.16% |
| Q3 2025 | 2.62% |
| Q2 2025 | 1171.04% |
| Q1 2025 | -113.63% |
| Q4 2024 | 0.54% |
| Q3 2024 | 68.47% |
| Q2 2024 | -47.37% |
| Q1 2024 | 17.88% |
| Q4 2023 | -46.54% |
| Q3 2023 | 15.16% |
| Q2 2023 | 59.27% |
| Q1 2023 | 89.90% |
| Q4 2022 | -62.06% |
| Q3 2022 | -16.34% |
| Q2 2022 | 14.40% |
| Q1 2022 | -15.57% |
| Q4 2021 | 9.13% |
| Q3 2021 | 11.71% |
| Q2 2021 | 5.98% |
| Q1 2021 | 13.82% |
| Q4 2020 | 61.40% |
| Q3 2020 | 6.82% |
| Q2 2020 | -11.69% |
| Q1 2020 | -42.10% |
| Q4 2019 | 87.04% |
| Q3 2019 | -28.08% |
| Q2 2019 | 87.86% |
| Q1 2019 | -10.95% |
| Q4 2018 | 80.01% |
| Q3 2018 | -63.98% |
| Q2 2018 | 21.46% |
| Q1 2018 | -23.15% |
| Q4 2017 | 15.40% |
| Q3 2017 | 2.82% |
| Q2 2017 | -10.47% |
| Q1 2017 | -21.43% |
| Q4 2016 | -10.00% |
| Q3 2016 | 18.73% |
| Q2 2016 | 11.99% |
| Q1 2016 | -64.09% |